Download Media Release

NEWS RELEASE
*** Embargoed until Wednesday 29th April 01:00 (BST) / Tuesday 28th April at
20:00 (EDT) ***
Improving the effect of HIV drugs by the use of a
vaccine
A vaccine containing a protein necessary for virus replication can boost an HIVinfected patient’s immune system, according to clinical research published in the
open access journal Retrovirology. This boost can result in increased
effectiveness of antiretroviral drugs.
When people are first diagnosed with HIV they are put on antiretroviral drugs,
also known as highly active antiretroviral therapy (HAART). These drugs can
stop the virus reproducing almost completely. When taking HAART, however, it
is known that the virus can still replicate at low levels and accumulate in a latent
form in what are called “reservoirs”. These reservoirs, located throughout the
body including the brain, bone marrow and genital tract, cannot be acted upon
by HAART and can cause complications and deaths due to non-AIDS related
diseases.
A vaccine was developed that targets the viral protein “Tat”, which is produced
early on in HIV infection. Tat has a key role in viral replication and progression
of the disease by weakening the immune system. By designing a vaccine that
included a small amount of the Tat protein, researchers were able to produce an
immune response to prevent disease progression.
Lead researcher, Barbara Ensoli, said: “We prove for the first time that
antiretroviral therapy may be intensified by a vaccine. These results open new
scenarios to investigate, namely whether this vaccine may help with virus
control where patients have low adherence to antiretroviral therapy, simplify
treatment, and reduce transmission of the disease.”
Researchers from the Italian National AIDS Center at Istituto Superiore di Sanità
(Rome, Italy) conducted a Phase II clinical trial that injected 168 HIV-infected
patients with the vaccine that contained either 7.5 micrograms or 30
micrograms of the Tat protein. For both doses, the participants received the
vaccine once a month over the course of either three or five months. None of the
participants had anti-Tat antibodies at the start of the trial and it was anticipated
that the vaccine would induce them. The patients also continued on HAART
treatment.
Patients were followed for three years (144 weeks). It was found that the
vaccine induced production of anti-Tat antibodies. A significant growth of CD4+
T cells was also seen, which is a sign of the immune system’s strength. There
was also an increase in the T, B and other immune cells. The biggest response
was seen amongst those who received the vaccine with 30 micrograms of Tat
over the course of three months. These effects were found to persist for all the
three years.
Those who received the vaccine also had a significant reduction in HIV “proviral”
DNA load, which acts as an indicator of the latent form of the virus in reservoirs.
This reduction was compared to a group of 79 patients receiving only HAART
enrolled in a separate observational study, which acted as reference group for
biomarkers of the disease. This is different from an internal control group.
The researchers see the results as very promising for the treatment of HIV in the
future. However, they await the results of future efficacy studies, and of a phase
II double-blinded trial of the vaccine with a control that has taken place in South
Africa, to confirm their findings.
-ENDSMedia Contact
Joel Winston
Media Officer
BioMed Central
T: +44 (0)20 3192 2081
E: [email protected]
Notes to editor:
1.
Research article
Fabrizio Ensoli, Aurelio Cafaro, Anna Casabianca, Antonella Tripiciano, Stefania Bellino,
Olimpia Longo, Vittorio Francavilla, Orietta Picconi, Cecilia Sgadari, Sonia Moretti, Maria
R Pavone Cossut, Angela Arancio, Chiara Orlandi, Leonardo Sernicola, Maria T
Maggiorella, Giovanni Paniccia, Cristina Mussini, Adriano Lazzarin, Laura Sighinolfi, Guido
Palamara, Andrea Gori, Gioacchino Angarano, Massimo Di Pietro, Massimo Galli, Vito S
Mercurio, Francesco Castelli, Giovanni Di Perri, Paolo Monini, Mauro Magnani, Enrico
Garaci and Barbara Ensoli
HIV-1 Tat immunization restores immune homeostasis and attacks the HAART-resistant
blood HIV DNA: results of a randomized phase II exploratory clinical trial
Retrovirology 2015
doi: 10.1186/s12977-015-0151-y
During embargo, article available here: http://bit.ly/1GmejUc
After embargo, article available at journal website here:
http://dx.doi.org/10.1186/s12977-015-0151-y
Please name the journal in any story you write. If you are writing for the web, please
link to the article. All articles are available free of charge, according to BioMed Central's
open access policy.
2.
Retrovirology is an open access, online journal that publishes stringently peerreviewed, high-impact articles on basic retrovirus research.
Retroviruses are pleiotropically found in animals. Well-described examples include avian,
murine and primate retroviruses. Two human retroviruses are especially important
pathogens. These are the human immunodeficiency virus, HIV, and the human T-cell
leukemia virus, HTLV. HIV causes AIDS while HTLV-I is the etiological agent for adult Tcell leukemia. There is a large amount of basic research being conducted on HIV and
HTLV-I spanning gene expression, virus structure-assembly, integration, replication, and
pathogenesis. Retrovirology intends to cover these areas of human and animal retrovirus
research.
3.
BioMed Central is an STM (Science, Technology and Medicine) publisher which has
pioneered the open access publishing model. All peer-reviewed research articles
published by BioMed Central are made immediately and freely accessible online, and are
licensed to allow redistribution and reuse. BioMed Central is part of Springer
Science+Business Media, a leading global publisher in the STM sector.
www.biomedcentral.com
Joel Winston
Media Officer
BioMed Central
236 Gray's Inn Road
London, WC1X 8HB
United Kingdom
T: +44 (0)20 3192 2081
M: +44 (0)7766540147
E: [email protected]
W: www.biomedcentral.com
Follow BioMed Central: